中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
10期
1248-1250
,共3页
付艳%杜楠%孙君重%康欢荣
付豔%杜楠%孫君重%康歡榮
부염%두남%손군중%강환영
香菇多糖%胃肿瘤%化学疗法
香菇多糖%胃腫瘤%化學療法
향고다당%위종류%화학요법
Lentinan%Gastric tumor%Chemotherapy
目的 观察香菇多糖联合化学疗法(化疗)治疗胃癌的疗效.方法 将82例胃癌患者完全随机分为观察组(42例)和对照组(40例).观察组采用香菇多糖加化疗,对照组采用单纯化疗.测定2组患者治疗前及治疗2周后外周血T淋巴细胞亚群和自然杀伤细胞活性,治疗2周后对患者疗效、免疫功能、生活质量及不良反应进行评价.结果 治疗后观察组和对照组总有效率分别为61.9％(26/42)和40％(18/40),2组比较差异有统计学意义(P＜0.05).观察组CD3、CD4、CD4/CD8比值、NK细胞活性明显高于治疗前[分别为(59±9)％比(50±8)％,(37±6)％比(34±4)％,(1.65±0.45)比(1.24±0.25),(37±8)％比(28±6)％],CDs低于治疗前[(24±4)％比(27±4)％],差异均有统计学意义(均P＜0.05)；对照组治疗后CD4/CD8比值、自然杀伤细胞活性明显低于治疗前[分别为(1.01±0.30)比(1.26 ±0.22),(24±6)％比(28±6)％],CD3高于治疗前[(51±7)％比(49±7)％],差异均有统计学意义(均P＜0.05)；观察组与对照组治疗后CD3、CD4、CD4/CD8比值、自然杀伤细胞活性比较差异均有统计学意义(均P＜0.05).观察组卡氏行为状态评分上升患者比率为47.6％(20/42),明显高于对照组[25.0％(10/40)](P ＜0.05).观察组血小板减低、白细胞减少发生率均明显低于对照组[28.6％(12/42)比45.0％(18/40),33.3％(14/42)比50.0％(20/40)],差异均有统计学意义(均P＜0.05).结论 香菇多糖联合化疗治疗胃癌的疗效优于单纯化疗,可提高患者免疫功能及临床疗效.
目的 觀察香菇多糖聯閤化學療法(化療)治療胃癌的療效.方法 將82例胃癌患者完全隨機分為觀察組(42例)和對照組(40例).觀察組採用香菇多糖加化療,對照組採用單純化療.測定2組患者治療前及治療2週後外週血T淋巴細胞亞群和自然殺傷細胞活性,治療2週後對患者療效、免疫功能、生活質量及不良反應進行評價.結果 治療後觀察組和對照組總有效率分彆為61.9％(26/42)和40％(18/40),2組比較差異有統計學意義(P＜0.05).觀察組CD3、CD4、CD4/CD8比值、NK細胞活性明顯高于治療前[分彆為(59±9)％比(50±8)％,(37±6)％比(34±4)％,(1.65±0.45)比(1.24±0.25),(37±8)％比(28±6)％],CDs低于治療前[(24±4)％比(27±4)％],差異均有統計學意義(均P＜0.05)；對照組治療後CD4/CD8比值、自然殺傷細胞活性明顯低于治療前[分彆為(1.01±0.30)比(1.26 ±0.22),(24±6)％比(28±6)％],CD3高于治療前[(51±7)％比(49±7)％],差異均有統計學意義(均P＜0.05)；觀察組與對照組治療後CD3、CD4、CD4/CD8比值、自然殺傷細胞活性比較差異均有統計學意義(均P＜0.05).觀察組卡氏行為狀態評分上升患者比率為47.6％(20/42),明顯高于對照組[25.0％(10/40)](P ＜0.05).觀察組血小闆減低、白細胞減少髮生率均明顯低于對照組[28.6％(12/42)比45.0％(18/40),33.3％(14/42)比50.0％(20/40)],差異均有統計學意義(均P＜0.05).結論 香菇多糖聯閤化療治療胃癌的療效優于單純化療,可提高患者免疫功能及臨床療效.
목적 관찰향고다당연합화학요법(화료)치료위암적료효.방법 장82례위암환자완전수궤분위관찰조(42례)화대조조(40례).관찰조채용향고다당가화료,대조조채용단순화료.측정2조환자치료전급치료2주후외주혈T림파세포아군화자연살상세포활성,치료2주후대환자료효、면역공능、생활질량급불량반응진행평개.결과 치료후관찰조화대조조총유효솔분별위61.9％(26/42)화40％(18/40),2조비교차이유통계학의의(P＜0.05).관찰조CD3、CD4、CD4/CD8비치、NK세포활성명현고우치료전[분별위(59±9)％비(50±8)％,(37±6)％비(34±4)％,(1.65±0.45)비(1.24±0.25),(37±8)％비(28±6)％],CDs저우치료전[(24±4)％비(27±4)％],차이균유통계학의의(균P＜0.05)；대조조치료후CD4/CD8비치、자연살상세포활성명현저우치료전[분별위(1.01±0.30)비(1.26 ±0.22),(24±6)％비(28±6)％],CD3고우치료전[(51±7)％비(49±7)％],차이균유통계학의의(균P＜0.05)；관찰조여대조조치료후CD3、CD4、CD4/CD8비치、자연살상세포활성비교차이균유통계학의의(균P＜0.05).관찰조잡씨행위상태평분상승환자비솔위47.6％(20/42),명현고우대조조[25.0％(10/40)](P ＜0.05).관찰조혈소판감저、백세포감소발생솔균명현저우대조조[28.6％(12/42)비45.0％(18/40),33.3％(14/42)비50.0％(20/40)],차이균유통계학의의(균P＜0.05).결론 향고다당연합화료치료위암적료효우우단순화료,가제고환자면역공능급림상료효.
Objective To observe the immunologic function and effect of lentinan combined with chemotherapy in treatment of gastric carcinoma.Methods Eighty-two cases of gastric carcinoma were randomly divided into observation group(42 cases)and control group(40 cases).The patients in treatment group were treated with lentinan and chemotherapy,and the patients in control group were treated with chemotherapy only.The therapeutic effect,immune functions,Karnofsky performance status(KPS)score,adverse effect in two groups were observed and compared.Results The total effective rate in observation group and control group was 61.9％(26/42)and 40％(18/40),and there was significant difference(P ＜ 0.05).Compared to before treatment,in observation group,CDs reduced,and CD3,CD4,CD4/CD8,nature kill(NK)cell increased,while in control group,CD4/CDs and NK cell reduced,CD3 increased,and there were significant differences(all P ＜ 0.05).There was significant difference in CD3,CD4,CD4/CDs,NK cell activity between observation group and control group (P ＜ 0.05).The rate of KPS score increasing in observation group was higher than that in control group.The rates of blood platelet decreasing and leucopenia in observation group were lower than those in control group. Conclusions Lentinan combined with chemotherapy can enhance some immunological function and clinical effect in patients with gastric carcinoma.So lentinan is an important remedy adjuvant of chemotherapy.
